Organisation paid for research Program year 2025 Source: CMS Open Payments

Sooner Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$2,782,383

412 payments

Through program year 2025, Sooner Clinical Research Inc is reported as receiving $2,782,383 in research payments, across 412 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $587,860 122
2024 Research $514,692 63
2023 Research $77,561 11
2022 Research $134,532 29
2021 Research $545,750 65
2020 Research $598,354 73
2019 Research $323,635 49

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $930,443 96 payments
  2. AbbVie, Inc. $487,406 72 payments
  3. ITI, Inc. $358,528 84 payments
  4. Sage Therapeutics, Inc. $355,718 62 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $231,793 13 payments
  6. Boehringer Ingelheim International GmbH $197,279 30 payments
  7. Neurocrine Biosciences, Inc. $91,106 21 payments
  8. Sumitomo Pharma America, Inc. $62,011 9 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $45,012 4 payments
  10. Sunovion Pharmaceuticals Inc. $14,469 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $341,542 21 payments
  2. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $291,781 20 payments
  3. Phase II DRF study of NR2B modulation in MDD $168,615 2 payments
  4. A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment $159,724 18 payments
  5. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $155,124 28 payments
  6. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $138,009 16 payments
  7. Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) $120,250 10 payments
  8. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $106,127 13 payments
  9. A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder $86,240 10 payments
  10. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $82,030 24 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record